Farmland Security Act of 2025 This bill authorizes increased civil penalties for violations of the Agricultural Foreign Investment Disclosure Act of 1978 (AFIDA) and increases Department of Agriculture (USDA) oversight of and research into foreign investment in agricultural land. As background, AFIDA and the regulations that implemented the act require foreign investors who acquire, transfer, or hold an interest in U.S. agricultural land to report such holdings and transactions to USDA. In general, the bill allows USDA to determine an appropriate civil penalty amount for an AFIDA violation by removing the cap that currently prohibits the civil penalty from exceeding 25% of the fair market value of the interest in the agricultural land associated with the violation. Under an exception in the bill, the civil penalty for a foreign-owned shell corporation is 100% of the fair market value of the interest in the agricultural land. The bill defines a shell corporation to include a company, association, firm, partnership, society, joint stock company, trust, or estate that has no or nominal operations. The penalty does not apply if the shell corporation remedies a defective filing or failure to file within 60 days of USDA providing notice. USDA must conduct annual compliance audits of at least 10% of the reports. Further, USDA must provide state and county-level personnel certain annual training. USDA must also annually conduct research and submit a report to Congress on foreign investment in agricultural land, including trends in the purchase of U.S. agricultural land by foreign-owned shell corporations.
Read twice and referred to the Committee on Agriculture, Nutrition, and Forestry.
Lobbying filed by NOVARTIS
Lobbying filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Lobbying filed by GSK (FKA GLAXOSMITHKLINE INC.)
Lobbying filed by GSK (FKA GLAXOSMITHKLINE INC.)
Lobbying filed by NOVARTIS
Read twice and referred to the Committee on Agriculture, Nutrition, and Forestry.
| Registrant | Client | Amount | Filed | Period | Issues |
|---|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $960.0M | Apr 22, 2024 | 2024Q1 | BUDCPTHCR |
| NOVARTIS | NOVARTIS | $351.0M | Apr 19, 2024 | 2024Q1 | BUDCPTHCR |
| GSK (FKA GLAXOSMITHKLINE INC.) |
Congress members who traded stocks in companies connected to lobbying on this bill, within 90 days of its introduction date.
| Member | Party | Ticker | Company | Trade | Date | Amount | Timing | Lobbying Client | Conflict |
|---|---|---|---|---|---|---|---|---|---|
| George Whitesides | D | NVS | NOVARTIS AG | Sell | Mar 24, 2025 | $100,001 - $250,000 | 20d after | NOVARTIS | 41% |
| Robert P. Bresnahan, Jr. | R | K |
4 trades by 3 members of Congress in companies connected to lobbying on S 845. The average conflict score is 37%.
CapitolExposed identifies the "bill-lobbying-trade pipeline" by: (1) finding lobbying filings (LD-2) that specifically mention this bill, (2) matching lobbying clients to publicly traded companies, and (3) finding stock trades by members of Congress in those companies within 90 days of the bill's introduction date. Trades made before the bill was introduced are highlighted in red, as they may indicate advance knowledge. This analysis surfaces correlations worthy of scrutiny; it does not prove wrongdoing.
Gilbert Ray Cisneros, Jr. bought K
Bill introduced
George Whitesides sold NVS
Robert P. Bresnahan, Jr. bought K
Gilbert Ray Cisneros, Jr. bought K
| GSK (FKA GLAXOSMITHKLINE INC.) |
| $151.0M |
| Jul 22, 2024 |
| 2024Q2 |
BUDCPTHCR |
| NOVARTIS | NOVARTIS | $101.0M | Jul 22, 2024 | 2024Q2 | BUDCPTHCR |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $82.0M | Apr 22, 2024 | 2024Q1 | BUDCPTHCR |
| NOVARTIS | NOVARTIS | $74.0M | Oct 21, 2024 | 2024Q3 | BUDCPTHCR |
| KELLEY DRYE & WARREN LLP | AFIDA MODERNIZATION COMMITTEE (INFORMAL COALITION) | $2.0M | Jul 21, 2025 | 2025Q2 | AGR |
| KELLEY DRYE & WARREN LLP | AFIDA MODERNIZATION COMMITTEE (INFORMAL COALITION) | $2.0M | Apr 21, 2025 | 2025Q1 | AGR |
| K |
| Buy |
| Apr 8, 2025 |
| $1,001 - $15,000 |
| 35d after |
| GSK (FKA GLAXOSMITHKLINE INC.) |
| 37% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 39d before | GSK (FKA GLAXOSMITHKLINE INC.) | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Apr 29, 2025 | $1,001 - $15,000 | 56d after | GSK (FKA GLAXOSMITHKLINE INC.) | 36% |